Mittelbiberach, Germany

Jochen Neu


 

Average Co-Inventor Count = 13.7

ph-index = 2

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Jochen Neu: Innovator in Azaindazole Compounds

Introduction

Jochen Neu is a notable inventor based in Mittelbiberach, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target specific receptors involved in autoimmune diseases. With a total of 2 patents, his work is paving the way for new therapeutic options.

Latest Patents

Jochen Neu's latest patents focus on Azaindazole compounds as CCR1 receptor antagonists. These compounds are disclosed as useful for treating a variety of diseases and disorders mediated or sustained through the activity of CCR1. This includes autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The patents also detail methods of making and using these compounds, showcasing their potential in medical applications.

Career Highlights

Jochen Neu is currently employed at Boehringer Ingelheim International GmbH, a leading global pharmaceutical company. His role involves extensive research and development in the field of drug discovery, where he applies his expertise to create innovative solutions for complex health issues.

Collaborations

Throughout his career, Jochen has collaborated with several talented individuals, including Brian Nicholas Cook and Christian Harcken. These collaborations have enhanced his research efforts and contributed to the advancement of their shared goals in pharmaceutical innovation.

Conclusion

Jochen Neu's work in the development of Azaindazole compounds represents a significant advancement in the treatment of autoimmune diseases. His contributions to the field, along with his collaborations, highlight the importance of innovation in medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…